-

Shareholder Alert: Robbins LLP Reminds Investors It Is Investigating the Officers and Directors of Tupperware Brands Corporation (TUP) on Behalf of Shareholders

SAN DIEGO & ORLANDO, Fla.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors it is investigating whether certain officers and directors of Tupperware Brands Corporation (NYSE: TUP) violated federal securities laws. Tupperware operates as a direct-to-consumer marketer of various products across a range of brands and categories in various regions.

If you suffered a loss as a result of Tupperware's misconduct, click here.

Tupperware Brands Corporation (TUP) Fails to File Annual Report On Time

On February 24, 2020, Tupperware announced that it would be unable to file its annual report for fiscal year ended December 28, 2019. The Company stated that the results were affected by "financial reporting issues" with its Fuller Mexico segment. Total impairments for Fuller Mexico are expected to be approximately $31 million. Tupperware is now currently conducting an investigation into accounting for its accounts payable and accrued liabilities at Fuller Mexico and the matter is $9-$11 million of the total expected $19-$21 million full year impact. Tupperware also stated "the Company is forecasting a need for relief concerning …its $650 million credit agreement… to avoid a potential acceleration of debt, which could have a material adverse impact on the Company." On this news, Tupperware's stock price fell 45.6% to close at $3.11.

Tupperware Brands Corporation (TUP) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
LKandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leonid Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:TUP

Release Versions
$Cashtags

Contacts

Leonid Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom